St. Jude Medical Gets FDA Approval For Its Axium Neurostimulator System For Pain

(RTTNews) - St. Jude Medical, Inc. (STJ) Wednesday said it received FDA approval of the St. Jude Medical Axium Neurostimulator System for dorsal root ganglion or DRG stimulation for patients suffering from chronic intractable pain.

The company noted that approval of DRG stimulation in the U.S. will ensure access to therapeutic approach for treating moderate to severe chronic intractable pain of the lower limbs in adult patients with complex regional pain syndrome.

St. Jude Medical Axium system delivers a form of spinal stimulation that gives physicians the ability to treat the specific areas of the body where pain occurs.

The approval of DRG stimulation was based in part on the results of the ACCURATE IDE study.

Chronic pain is found to affect approximately 1.5 billion people worldwide.